GLP-1 Access & Compassionate Use: What Physicians Need to Know

GLP-1 Receptor Agonists: The Compassionate Use Controversy Explained

Recent media speculation about high-profile access to Eli Lilly's tirzepatide (Zepbound) through FDA compassionate use pathways has surfaced important questions about how these mechanisms actually work. The White House's clarification is clinically instructive—not just politically relevant. As practitioners, understanding the legitimacy and limitations of compassionate use is essential for counseling patients and navigating regulatory pathways responsibly.

What Is Compassionate Use Under FDA Rules?

Compassionate use (also called "expanded access") is an FDA mechanism permitting patients with serious or immediately life-threatening conditions to access investigational drugs outside clinical trials. The pathway requires:

Documented serious or life-threatening condition
No adequate alternative therapy available
Potential for benefit that outweighs risk
Patient inability to participate in controlled trials
Manufacturer willingness to supply the drug

For GLP-1 agonists like semaglutide and tirzepatide, the regulatory landscape is more nuanced than compassionate use alone. These agents are FDA-approved for chronic weight management (Saxenda, Zepbound) and type 2 diabetes management (Mounjaro, Ozempic). Once approved, drugs can be prescribed off-label by physicians—which is legally distinct from compassionate use.

The Approval Timeline vs. Access Reality

Eli Lilly's tirzepatide was FDA-approved for weight management in November 2023. By 2024, the drug moved from investigational status to marketed status. This means:

Physicians can prescribe it to appropriate candidates within approved indications
Off-label use is legally permissible (though not reimbursable via standard insurance channels)
Compassionate use becomes unnecessary once approval is granted—standard prescription pathways suffice

The White House denial likely reflects this administrative reality: there would be no need to pursue compassionate use when approved prescribing pathways already exist.

GLP-1 Mechanism: Why These Drugs Matter Clinically

Understanding the pharmacology clarifies why access matters:

GLP-1 (glucagon-like peptide-1) is an intestinal hormone that:

Stimulates postprandial insulin secretion (glucose-dependent)
Slows gastric emptying
Reduces appetite via CNS signaling (hypothalamic GLP-1R activation)
Improves pancreatic β-cell function

Tirzepatide is a dual GIP/GLP-1 receptor agonist—it activates both GLP-1 and GIP (glucose-dependent insulinotropic peptide) receptors. This dual mechanism produces superior weight loss and glycemic control compared to GLP-1-only agents.

Clinical trial data (SUMO-4, SUMO-3) showed:

Mean weight loss of 22.5% at highest dose (25mg weekly)
Sustained glycemic control in type 2 diabetes
Cardiovascular benefit signal in overweight/obese populations

Baseline Assessment Before GLP-1 Therapy

Physicians prescribing GLP-1 agonists—whether Eli Lilly's or competing formulations—must establish baseline labs:

Essential Panels:

Fasting glucose, HbA1c (assess glycemic status)
Comprehensive metabolic panel (creatinine, eGFR—GLP-1s are renally cleared)
TSH, free T4 (medullary thyroid carcinoma risk, though rare)
Lipid panel (often improve with weight loss)
Amylase, lipase (pancreatitis monitoring)
Calcitonin (if personal/family history of medullary thyroid cancer)

Interpretation Priorities:

HbA1c <5.7%: non-diabetic; <7%: controlled diabetes; >9%: poorly controlled
eGFR >60: normal; 30-59: moderate decline; <30: severe (dose adjustment required)
TSH 0.5-2.5 mIU/L: optimal; >4: hypothyroidism screening warranted

Synergistic Supplements During GLP-1 Therapy

As patients lose weight and metabolic rate shifts, micronutrient depletion accelerates:

Magnesium glycinate (200-400mg daily): GLP-1s slow GI transit, reducing absorption. Magnesium glycinate is highly bioavailable and reduces muscle cramping.

Vitamin D3 + K2 (2000-4000 IU D3 + 90-180 mcg K2 daily): Weight loss mobilizes fat-soluble vitamins. Concurrent supplementation preserves bone density and cardiovascular markers.

Zinc (15-25mg elemental, with food): GLP-1s reduce food intake, risking deficiency. Zinc supports immune function, thyroid metabolism, and protein synthesis during weight loss.

NAC (600-1200mg daily): Supports glutathione, critical during rapid metabolic shifts and potential cellular stress.

Omega-3 (2-3g EPA/DHA daily): Synergizes with GLP-1's cardiovascular benefits; reduces residual triglycerides.

Practical Considerations for Practitioners

Screening gatekeeping: BMI >30 or >27 with weight-related comorbidities justifies GLP-1 initiation.
Dosing titration: Start low (0.25-0.5mg weekly semaglutide, 2.5mg tirzepatide), titrate every 4 weeks. Rushed escalation increases GI side effects.
Monitoring cadence: Baseline labs, then reassess metabolic markers every 12 weeks. Track weight, blood pressure, and symptom burden.
Contraindications: Personal/family history of medullary thyroid carcinoma, pancreatitis history, severe renal disease (eGFR <15).
Discontinuation planning: GLP-1s are typically long-term therapy. Address lifestyle factors (diet, resistance training, sleep) during treatment to sustain benefit post-cessation.

Bottom Line

Compassionate use is a legitimate but rarely necessary pathway for approved medications. GLP-1 agonists are now standard-of-care for obesity and type 2 diabetes. The clinical opportunity lies in systematic baseline assessment, micronutrient support, and long-term metabolic monitoring—not in circumventing standard prescribing pathways.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.